Needle-free, inhalant powder measles vaccine could save thousands of livesAugust 17, 2009The first dry powder inhalable vaccine for measles is moving toward clinical trials next year in India, where the disease still sickens millions of infants and children and kills almost 200,000 annually, according to a report presented here today at the 238th National Meeting of the American Chemical Society (ACS). Robert Sievers, Ph.D., who leads the team that developed the dry-powder vaccine, said it's a perfect fit for use in back-roads areas of developing countries. Those areas often lack the electricity for refrigeration, clean water and sterile needles needed to administer traditional liquid vaccines. "Childhood vaccines that can be inhaled and delivered directly to mucosal surfaces have the potential to offer significant advantages over injection," Sievers said. "Not only might they reduce the risk of infection from HIV, hepatitis, and other serious diseases due to unsterilized needles, they may prove more effective against disease." "Many serious infections, such as the measles virus, can enter the body through inhalation. Measles vaccine dry powders have the potential to effectively vaccinate infants, children and adults by inhalation, avoiding the problems associated with liquid vaccines delivered by injection," he added. Although made for developing countries, the technology eventually could become the basis for a new generation of inhalable - and ouchless vaccines - in the United States and elsewhere. So far, an inhalable vaccine is available for only one disease. It is a wet mist vaccine for influenza. Sievers, once an atmospheric scientist and who now is with Department of Chemistry and Biochemistry and Center for Pharmaceutical Biotechnology, University of Colorado, Boulder, took inspiration for the new vaccine from research on how people inhale tiny airborne droplets of air pollutants. To create an inhalable vaccine, Sievers and his team of students and researchers developed a patented process known as the "Carbon Dioxide-Assisted Nebulization with a Bubble Dryer," called CAN-BD. The weakened measles virus is mixed with "supercritical" carbon dioxide - part gas, part liquid - to produce microscopic bubbles and droplets, which then are dried to make an inhalable powder. The powder is puffed into a small, cylindrical, plastic sack, with an opening like the neck of a plastic water bottle, and administered. "By taking one deep breath from the sack, a child could be effectively vaccinated," Sievers said. In animal tests, the inhaler has been just as effective in delivering measles vaccine as the traditional injection, the researchers say. They now are working on an inexpensive dry powder inhaler that would deliver measles or influenza vaccines to developing nations and could be used elsewhere. In replacing injections, the new method also would help reach those who refuse inoculations because of their fear of needles. The researchers say that the vaccine could be produced for about 26 cents a dose. If the inhaler passes final safety and effectiveness tests, the Serum Institute of India Ltd. expects a demand growing to 400 million doses of measles vaccine a year, according to Sievers. "Human clinical trials are expected to begin next year in India, after animal safety studies are completed this year," Sievers said. "About two-thirds of the world's deaths due to measles occur in that nation. Worldwide, several hundred people die every day from measles-related disease," he added. In earlier research in the 1980s in Mexico during a measles outbreak, 3 million children received a measles vaccine by inhaling a wet mist aerosol and those who took part in the test had a lower rate of developing measles than those who received a vaccine by injection, according to Sievers. "The problem with that method," he said, "was that the wet mists required power or batteries to generate the aerosol and the liquid vaccines had to be freshly made up and kept on ice and the nebulizer that delivers the dose had to be cleaned. The new, inexpensive dry aerosol dispenser doesn't need to be cleaned and doesn't require power," he said. American Chemical Society |
|||||||||||||||||||||
| Related Measles Vaccine Current Events and Measles Vaccine News Articles New vaccine delivery may be more effective against measles Worldwide, there are estimated to be 10 million cases of measles and 197,000 deaths from the disease each year. While vaccines exist to protect children against measles, the vaccines are often difficult to store, costly to transport and may be prone to contamination when shipped to developing countries. Dry season brings on measles in sub-Saharan Africa Measles epidemics in Niger fluctuate wildly from one season to another but the timing of the outbreaks always coincides with the end of the annual rainy season, according to an international team of researchers. HIV-infected infants respond poorly to childhood vaccination It is known that HIV-infected children who do not receive appropriate antiretroviral drugs experience immune depression, and may become susceptible to infectious diseases that would otherwise be prevented by childhood immunization. Studies affirm need for influenza and measles vaccinations in HIV-infected patients Two new studies emphasize the importance of delivering measles and influenza vaccines to HIV-infected individuals. Both studies are published in the August 1 issue of The Journal of Infectious Diseases, now available online. Measles Vaccinations Need to be Repeated to Protect HIV-Infected Children HIV-infected children may require repeat measles vaccination for protection, according to new research from the Johns Hopkins Bloomberg School of Public Health and other institutions. Investigating the measles virus as a tool to kill multiple myeloma Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure. This is the third of a series of molecular medicine studies in patients testing the potential of measles to kill cancer. Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer Mayo Clinic Cancer Center has opened a new clinical study using a vaccine strain of the measles virus to attack recurrent glioblastoma multiforme, a largely untreatable brain tumor. This is the second of several pending molecular medicine studies in patients using measles to kill cancer. Mayo Clinic researchers enhance safety and effectiveness of therapeutic virus that fights cancer Mayo Clinic researchers working with colleagues in Germany have devised a much-needed multilevel safety feature for viruses used to treat cancer. NEW APPROACH TO INFANT MALARIA AND ANAEMIA CONTROL (p 1471) A new approach to malaria and anaemia control involving drug treatment delivered at the time of an existing WHO immunisation schedule could substantially reduce illness and death from malaria among infants, conclude authors of a study in this week's issue of THE LANCET. An estimated 1 000 000 malaria deaths per year underline the need for improved malaria control. Clinical malaria and severe anaemia are major causes of paediatric hospital admission and death in many malaria-endemic settings. In the absence of an effective and affordable vaccine, control programmes continue to rely on case management while attempting the large-scale deployment of insecticide-treated nets. David Schellenberg a More Measles Vaccine Current Events and Measles Vaccine News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||